M3, Inc. (MTHRF) will report fiscal earnings on April 24, 2026. The healthcare information services company faces investor scrutiny as analysts expect $0.0885 earnings per share and $564.53 million in revenue. These estimates represent a significant slowdown from recent quarters. M3 operates five business segments serving physicians and healthcare professionals globally. The company’s stock trades at $11.00 with a $7.45 billion market cap. Meyka AI rates MTHRF with a grade of B+, reflecting solid fundamentals despite recent headwinds. Understanding what to watch helps investors prepare for this critical earnings release.
What Analysts Expect From MTHRF Earnings
Analysts project MTHRF will deliver modest earnings this quarter. The $0.0885 EPS estimate marks a sharp decline from the prior quarter’s $0.1784 actual EPS. Revenue expectations of $564.53 million sit below the previous quarter’s $597.21 million. This represents a concerning trend for investors monitoring M3’s performance.
EPS Expectations and Trends
The current EPS estimate of $0.0885 is the lowest in the past five quarters. Looking back, M3 reported $0.1784 in February 2026, $0.1084 in November 2025, and $0.1204 in August 2025. The company has shown volatility, but this quarter’s estimate suggests a material pullback. Earnings per share directly impacts stock valuation and investor confidence.
Revenue Forecast Analysis
Revenue estimates of $564.53 million fall short of recent quarters. The February quarter brought $597.21 million, while November delivered $572.47 million. This downward trajectory raises questions about M3’s growth momentum. Healthcare information services demand typically remains stable, making this decline noteworthy for analysts and investors tracking the stock.
Historical Performance and Beat/Miss Pattern
M3 has demonstrated a mixed track record on earnings surprises. Recent quarters show the company beating EPS estimates more often than missing them. Understanding this pattern helps predict April’s outcome.
Recent Quarter Results
In February 2026, M3 beat EPS estimates by delivering $0.1784 actual versus $0.1393 estimated. That’s a 28% beat. November 2025 saw $0.1084 actual versus $0.09463 estimated, a 15% beat. August 2025 delivered $0.1204 actual versus $0.1152 estimated, a 4.5% beat. The company has beaten EPS in three consecutive quarters, establishing a positive surprise pattern.
Revenue Performance Comparison
Revenue results show similar strength. February’s $597.21 million actual beat $595.57 million estimated by 0.3%. November’s $572.47 million beat $623.78 million estimated by missing 8.2%. August’s $595.24 million beat $566.23 million estimated by 5.1%. M3 shows stronger EPS execution than revenue consistency, suggesting operational efficiency improvements.
Key Metrics and What Investors Should Watch
Beyond headline numbers, several metrics deserve investor attention. M3’s valuation, profitability margins, and segment performance will shape market reaction to earnings.
Valuation and Profitability Metrics
MTHRF trades at a 26.19 PE ratio, above historical averages for healthcare services. The company maintains a 14.91% net profit margin, indicating solid operational efficiency. Return on equity stands at 17.55%, showing management generates decent returns on shareholder capital. These metrics suggest the market prices in growth expectations that earnings must validate.
Segment Performance and Growth Drivers
M3 operates five segments: Medical Platform, Evidence Solution, Career Solution, Site Solution, and Overseas. Investors should monitor which segments drive growth. The Medical Platform typically generates the largest revenue base. International expansion, particularly in the Overseas segment, represents a key growth opportunity. Management commentary on segment trends will be critical for assessing future momentum and competitive positioning in healthcare technology.
Meyka AI Grade and Investment Outlook
Meyka AI rates MTHRF with a grade of B+, reflecting balanced strengths and concerns. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating suggests MTHRF offers reasonable value but carries execution risks.
What the B+ Grade Means
The B+ grade indicates MTHRF performs adequately relative to peers and benchmarks. The company scores well on fundamental metrics like ROE and profitability. However, recent earnings estimate reductions and stock price weakness from $15.25 year-high to $11.00 current suggest market concerns. The grade reflects this mixed picture: solid fundamentals paired with near-term uncertainty.
Analyst Consensus and Future Outlook
Current analyst consensus leans toward Hold, with one analyst rating the stock neutral. No strong buy or sell recommendations exist, indicating balanced sentiment. The company’s ability to beat April estimates could shift sentiment positively. Conversely, missing estimates might trigger downgrades. M3’s long-term growth prospects depend on healthcare digital transformation adoption and international expansion success.
Final Thoughts
M3, Inc. faces a critical earnings test on April 24, 2026, with analysts expecting $0.0885 EPS and $564.53M revenue. Historical data shows the company has beaten EPS estimates in three consecutive quarters, suggesting potential for another positive surprise. However, the sharp decline in both EPS and revenue estimates raises legitimate concerns about growth momentum. Investors should focus on segment performance, international expansion progress, and management guidance on future quarters. The B+ Meyka AI grade reflects solid fundamentals, but execution matters. M3’s ability to stabilize revenue and maintain profitability margins will determine whether the stock can recover from i…
FAQs
What EPS and revenue does MTHRF need to beat estimates?
Analysts expect $0.0885 EPS and $564.53M revenue. To beat, MTHRF needs $0.095+ EPS and $575M+ revenue. Historical patterns show the company typically exceeds estimates by 4-28%, making these targets achievable with stable operations.
How does the current EPS estimate compare to recent quarters?
The $0.0885 estimate is the lowest in five quarters, down 50% from February’s $0.1784. Recent actuals: $0.1084 (Nov), $0.1204 (Aug). This decline signals significant earnings pressure or one-time items affecting profitability.
What does the B+ Meyka AI grade mean for MTHRF?
The B+ grade indicates solid fundamentals with balanced risk, factoring in S&P 500 comparison, sector performance, and analyst consensus. MTHRF appears reasonably valued but faces near-term execution risks that earnings will clarify.
Will M3 likely beat or miss April earnings estimates?
M3 has beaten EPS three consecutive quarters, establishing positive momentum. However, the sharp estimate decline suggests lower expectations. A beat remains likely if operations stay stable, but weakness in healthcare IT spending could cause a miss.
What should investors watch during the earnings call?
Monitor segment performance, international expansion progress, healthcare IT spending commentary, and management guidance. Watch for margin pressure explanations and competitive positioning updates. Management’s tone on growth prospects signals estimate sustainability.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)